Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its ...

Des Moines brewery named best brewpub in US for second year in a row

Des Moines' Lua Brewing has once again claimed the top spot as the No.1 brewpub in the country in the USA TODAY 10BEST ...
Yahoo Finance

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
MassDevice

Novocure has reimbursement win for Optune Lua in Japan

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its ...
Business Wire

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Cure Today

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...